{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T12:50:02Z","timestamp":1761569402591,"version":"build-2065373602"},"reference-count":32,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.clgc.2022.07.005","type":"journal-article","created":{"date-parts":[[2022,7,16]],"date-time":"2022-07-16T19:12:55Z","timestamp":1657998775000},"page":"183-193","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Review of Toxicities of PARP Inhibitors in Metastatic Castrate Resistant Prostate Cancer"],"prefix":"10.1016","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2612-9502","authenticated-orcid":false,"given":"Udit","family":"Nindra","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun Hee","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bavanthi","family":"Balakrishnar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abhijit","family":"Pal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Chua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.clgc.2022.07.005_bib0001","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1470-2045(19)30684-9","article-title":"Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial","volume":"21","author":"Mateo","year":"2020","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.clgc.2022.07.005_bib0002","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/s41391-020-0233-3","article-title":"PARP inhibitors as a new therapeutic option in metastatic prostate cancer: a systematic review","volume":"23","author":"Ratta","year":"2020","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"2","key":"10.1016\/j.clgc.2022.07.005_bib0003","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/PAS.0000000000000530","article-title":"The 2014 International Society of Urological Pathology (ISUP) consensus conference on gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system","volume":"40","author":"Epstein","year":"2016","journal-title":"Am J Surg Pathol"},{"issue":"11","key":"10.1016\/j.clgc.2022.07.005_bib0004","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.trecan.2020.05.011","article-title":"DNA Damage repair deficiency in prostate cancer","volume":"6","author":"Burdak-Rothkamm","year":"2020","journal-title":"Trends Cancer"},{"key":"10.1016\/j.clgc.2022.07.005_bib0005","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/4986365","article-title":"BRCA mutations in prostate cancer: prognostic and predictive implications","volume":"2020","author":"Messina","year":"2020","journal-title":"J Oncol"},{"issue":"5","key":"10.1016\/j.clgc.2022.07.005_bib0006","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1056\/NEJMoa1603144","article-title":"Inherited DNA-repair gene mutations in men with metastatic prostate cancer","volume":"375","author":"Pritchard","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2022.07.005_bib0007","doi-asserted-by":"crossref","first-page":"8105","DOI":"10.2147\/CMAR.S227033","article-title":"PARP inhibitors in metastatic prostate cancer: evidence to date","volume":"12","author":"Nizialek","year":"2020","journal-title":"Cancer Manag Res"},{"issue":"6330","key":"10.1016\/j.clgc.2022.07.005_bib0008","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1126\/science.aam7344","article-title":"PARP inhibitors: synthetic lethality in the clinic","volume":"355","author":"Lord","year":"2017","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.clgc.2022.07.005_bib0009","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.euo.2020.07.005","article-title":"When and How to Use PARP Inhibitors in prostate cancer: a systematic review of the literature with an update on on-going trials","volume":"3","author":"Antonarakis","year":"2020","journal-title":"Eur Urol Oncol"},{"issue":"5","key":"10.1016\/j.clgc.2022.07.005_bib0010","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1007\/s10637-014-0099-0","article-title":"Targeting DNA repair with combination veliparib (ABT-888) and temozolomide in patients with metastatic castration-resistant prostate cancer","volume":"32","author":"Hussain","year":"2014","journal-title":"Invest New Drugs"},{"issue":"18","key":"10.1016\/j.clgc.2022.07.005_bib0011","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1056\/NEJMoa1506859","article-title":"DNA-repair defects and olaparib in metastatic prostate cancer","volume":"373","author":"Mateo","year":"2015","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.clgc.2022.07.005_bib0012","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1200\/JCO.2017.75.7310","article-title":"Targeting androgen receptor and dna repair in metastatic castration-resistant prostate cancer: results from NCI 9012","volume":"36","author":"Hussain","year":"2018","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clgc.2022.07.005_bib0013","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s40425-018-0463-2","article-title":"Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations","volume":"6","author":"Karzai","year":"2018","journal-title":"J Immunother Cancer"},{"issue":"7","key":"10.1016\/j.clgc.2022.07.005_bib0014","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/S1470-2045(18)30365-6","article-title":"Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"19","author":"Clarke","year":"2018","journal-title":"Lancet Oncol"},{"issue":"32","key":"10.1016\/j.clgc.2022.07.005_bib0015","doi-asserted-by":"crossref","first-page":"3763","DOI":"10.1200\/JCO.20.01035","article-title":"Rucaparib in men with metastatic castration-resistant prostate cancer harboring a BRCA1 or BRCA2 gene alteration","volume":"38","author":"Abida","year":"2020","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1016\/j.clgc.2022.07.005_bib0016","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for metastatic castration-resistant prostate cancer","volume":"382","author":"de Bono","year":"2020","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.clgc.2022.07.005_bib0017","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/S1470-2045(21)00376-4","article-title":"Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial","volume":"22","author":"de Bono","year":"2021","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.clgc.2022.07.005_bib0018","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s00280-021-04249-7","article-title":"Niraparib with androgen receptor-axis-targeted therapy in patients with metastatic castration-resistant prostate cancer: safety and pharmacokinetic results from a phase 1b study (BEDIVERE)","volume":"88","author":"Saad","year":"2021","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"10.1016\/j.clgc.2022.07.005_bib0019","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/S1470-2045(21)00757-9","article-title":"Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial","volume":"23","author":"Smith","year":"2022","journal-title":"Lancet Oncol"},{"issue":"6_suppl","key":"10.1016\/j.clgc.2022.07.005_bib0020","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1200\/JCO.2020.38.6_suppl.100","article-title":"KEYNOTE-365 cohort a updated results: Pembrolizumab (pembro) plus olaparib in docetaxel-pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)","volume":"38","author":"Yu","year":"2020","journal-title":"J Clin Oncol"},{"issue":"6_suppl","key":"10.1016\/j.clgc.2022.07.005_bib0021","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1200\/JCO.2022.40.6_suppl.012","volume":"40","author":"Chi","year":"2022","journal-title":"J Clin Oncol"},{"issue":"6_suppl","key":"10.1016\/j.clgc.2022.07.005_bib0022","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1200\/JCO.2022.40.6_suppl.011","article-title":"PROpel: Phase III trial of olaparib (ola) and abiraterone (abi) versus placebo (pbo) and abi as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)","volume":"40","author":"Saad","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2022.07.005_bib0023","unstructured":"Therapeutic Goods Administration (TGA). Australian public assessment report for olaparib: department of health; 2019. Available at: https:\/\/www.tga.gov.au\/sites\/default\/files\/auspar-olaparib-190211.pdf, February 1st 2022."},{"issue":"3","key":"10.1016\/j.clgc.2022.07.005_bib0024","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1111\/jcpt.13349","article-title":"Haematologic toxicities with PARP inhibitors in cancer patients: an up-to-date meta-analysis of 29 randomized controlled trials","volume":"46","author":"Wang","year":"2021","journal-title":"J Clin Pharm Ther"},{"issue":"Suppl 4","key":"10.1016\/j.clgc.2022.07.005_bib0025","first-page":"A524","article-title":"EP993\u2005macrocytosis associated with olaparib","volume":"29","author":"Takenaka","year":"2019","journal-title":"Int J Gynecol Cancer"},{"issue":"11","key":"10.1016\/j.clgc.2022.07.005_bib0026","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1158\/1078-0432.CCR-20-0394","article-title":"Non-BRCA DNA damage repair gene alterations and response to the parp inhibitor rucaparib in metastatic castration-resistant prostate cancer: analysis from the phase ii triton2 study","volume":"26","author":"Abida","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.clgc.2022.07.005_bib0027","doi-asserted-by":"crossref","first-page":"e109","DOI":"10.1634\/theoncologist.2019-0229","article-title":"Real-world delivery of rucaparib to patients with ovarian cancer: recommendations based on an integrated safety analysis of ariel2 and study 10","volume":"25","author":"Drew","year":"2020","journal-title":"The oncologist"},{"issue":"7","key":"10.1016\/j.clgc.2022.07.005_bib0028","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1136\/ijgc-2020-001288","article-title":"Manage wisely: poly (ADP-ribose) polymerase inhibitor (PARPi) treatment and adverse events","volume":"30","author":"Madariaga","year":"2020","journal-title":"Int J Gynecol Cancer"},{"issue":"8","key":"10.1016\/j.clgc.2022.07.005_bib0029","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/S1470-2045(18)30333-4","article-title":"Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16\/NOVA): results from a double-blind, phase 3, randomised controlled trial","volume":"19","author":"Oza","year":"2018","journal-title":"Lancet Oncol"},{"issue":"32","key":"10.1016\/j.clgc.2022.07.005_bib0030","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1093\/jncimonographs\/lgh025","article-title":"Evidence-based treatment for cancer-related fatigue","volume":"04","author":"Mock","year":"2004","journal-title":"J Natl Cancer Inst Monogr"},{"issue":"1","key":"10.1016\/j.clgc.2022.07.005_bib0031","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1080\/03009742.2020.1732462","article-title":"Olaparib-related seronegative inflammatory arthritis: f\u0131rst report in the literature","volume":"50","author":"Kobak","year":"2021","journal-title":"Scand J Rheumato"},{"issue":"25","key":"10.1016\/j.clgc.2022.07.005_bib0032","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","article-title":"Niraparib in patients with newly diagnosed advanced ovarian cancer","volume":"381","author":"Gonz\u00e1lez-Mart\u00edn","year":"2019","journal-title":"N Eng J Med"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767322001574?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767322001574?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:36:45Z","timestamp":1761565005000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767322001574"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S1558767322001574"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2022.07.005","relation":{},"ISSN":["1558-7673"],"issn-type":[{"type":"print","value":"1558-7673"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Review of Toxicities of PARP Inhibitors in Metastatic Castrate Resistant Prostate Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2022.07.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2022 Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}